Advertisement

Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers

  • Elliot OffmanEmail author
  • Michael Davidson
  • Mohammad Abu-Rashid
  • Peng Chai
  • Catarina Nilsson
Original Research Article

Abstract

Background

Omega-3 carboxylic acids (OM3-CA) contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in free fatty acid form. Per gram, OM3-CA includes approximately half as much EPA as icosapent ethyl (IPE), an ethyl ester formulation of EPA.

Objective

The study aim was to assess systemic EPA and EPA + DHA exposures and plasma lipid parameters following multiple OM3-CA or IPE doses under low-fat dietary conditions, and dose proportionality after OM3-CA administration.

Methods

In this phase 1, two-cohort, open-label study (N = 114), participants following the Therapeutic Lifestyle Changes diet received either OM3-CA 2 g once daily for 10 days then OM3-CA 4 g once daily for 10 days, or IPE 2 g twice daily for 20 days. Exposure was considered similar if the 90% confidence intervals (CIs) of geometric least-squares mean (LSM) ratios for key pharmacokinetic parameters were within 80–125%.

Results

Baseline-adjusted steady-state EPA exposure was similar after dosing with OM3-CA 4 g/day versus IPE 4 g/day (LSM ratio, area under the concentration–time curve from time 0 to 24 h: 93.9%; 90% CI 85.6, 103.0). Combined molar-equivalent EPA + DHA exposure was 30.6% higher following OM3-CA 4 g/day than IPE 4 g/day. EPA and DHA exposure increased approximately proportionally with OM3-CA dose (2–4 g/day). Changes from baseline in lipid parameters were similar in the two cohorts.

Conclusion

EPA exposure from OM3-CA and IPE was similar under low-fat dietary conditions, despite OM3-CA containing only approximately half as much EPA as IPE. EPA and DHA exposure from OM3-CA increased proportionally with dose.

Keywords

Ethyl Ester Dose Proportionality Therapeutic Lifestyle Change Free Fatty Acid Form Icosapent Ethyl 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Medical writing support was provided by Dr Anja Becher of Oxford PharmaGenesis, Oxford, UK, and was funded by AstraZeneca. We thank Doug Kling and Judith Johnson for their participation in aspects of the study design, Sandra Connolly for her involvement in the study conduct and David Katzer for the statistical analyses.

Compliance with Ethical Standards

Ethical approval

All procedures performed in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The study protocol underwent review by the Chesapeake Research Review Inc. Institutional Review Board (Columbia, MD, USA) in compliance with US Code of Federal Regulations and International Conference on Harmonisation guidelines. All participants provided their written informed consent.

Funding

This study was sponsored by AstraZeneca.

Conflict of interest

Elliot Offman, Mohammad Abu-Rashid and Peng Chai are employees of Celerion, which received research funding for participation in this study from Omthera Pharmaceuticals, which is a subsidiary of AstraZeneca. Michael Davidson was an employee of AstraZeneca at the time that the study was conducted. Catarina Nilsson is an employee of AstraZeneca.

References

  1. 1.
    Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13:159.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8(1):94–106.CrossRefPubMedGoogle Scholar
  4. 4.
    Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012;142(3):614S–25S.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schwellenbach LJ, Olson KL, McConnell KJ, Stolcpart RS, Nash JD, Merenich JA. The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides. J Am Coll Nutr. 2006;25(6):480–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Davidson MH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013;24(6):467–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O. Fatty acid regulation of hepatic gene transcription. J Nutr. 2005;135(11):2503–6.PubMedGoogle Scholar
  9. 9.
    Mori TA, Burke V, Puddey IB, Watts GF, O’Neal DN, Best JD, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71(5):1085–94.PubMedGoogle Scholar
  10. 10.
    Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–38.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Allaire J, Couture P, Leclerc M, Charest A, Marin J, Lepine MC, et al. Randomized, crossover, head-to-head comparison of EPA and DHA supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA Study. Am J Clin Nutr. 2016;104(2):280–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016;30(8):2792–801.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014;19(1):21–36.CrossRefPubMedGoogle Scholar
  14. 14.
    Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40(3):315–27.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015;15(8):511–23.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6(6):573–84.CrossRefPubMedGoogle Scholar
  17. 17.
    Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013;9:563–73.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Epanova (package insert) Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014.Google Scholar
  19. 19.
    Vascepa (package insert) Bedminster, NJ: Amarin Pharma Inc. 2012.Google Scholar
  20. 20.
    Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.CrossRefGoogle Scholar
  21. 21.
    Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102(18):2284–99.CrossRefPubMedGoogle Scholar
  22. 22.
    Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1):5–18.CrossRefPubMedGoogle Scholar
  23. 23.
    Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13(6):474–83.CrossRefPubMedGoogle Scholar
  24. 24.
    Anderson BM, Ma DW. Are all n-3 polyunsaturated fatty acids created equal? Lipids Health Dis. 2009;8:33.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Elliot Offman
    • 1
    Email author
  • Michael Davidson
    • 2
    • 3
  • Mohammad Abu-Rashid
    • 1
    • 4
  • Peng Chai
    • 4
  • Catarina Nilsson
    • 5
  1. 1.Clinical Pharmacology and Pharmacometrics, CelerionMontrealCanada
  2. 2.Department of CardiologyUniversity of Chicago Pritzker School of MedicineChicagoUSA
  3. 3.Corvidia TherapeuticsWalthamUSA
  4. 4.Data Management and Biometrics, CelerionMontrealCanada
  5. 5.Quantitive Clinical PharmacologyAstraZeneca GothenburgMölndalSweden

Personalised recommendations